CNSY
Cerenome·NASDAQ
--
--(--)
--
--(--)
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About CNSY
Cerenome, Inc.
A U.S. pharmaceutical company that develops innovative, targeted radiotherapeutics for cancers
6420 Levit Green Boulevard, Suite 310, Houston, TX
Develops targeted radiotherapeutics for CNS(central nervous system) cancers.
Cerenome, Inc., was originally incorporated as a California general partnership in July 1996 and was incorporated in Delaware in May 1997. The Company is an American healthcare company focused on the development and commercialization of precise diagnosis and targeted radiopharmaceuticals for central nervous system (" CNS ") cancers. CNSide Diagnostics, LLC, its wholly-owned subsidiary, develops and commercializes proprietary laboratory-developed tests, such as CNSide, designed to identify tumor cells that have metastasized to the central nervous system in cancer and melanoma patients.
Company Financials
EPS
CNSY has released its 2026 Q1 earnings. EPS was reported at -1.05, versus the expected -0.85, missing expectations. The chart below visualizes how CNSY has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
CNSY has released its 2026 Q2 earnings report, with revenue of 411.00K, reflecting a YoY change of -70.43%, and net profit of -9.01M, showing a YoY change of -274.84%. The Sankey diagram below clearly presents CNSY's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
